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Glaucoma is a degenerative retinal disease characterized by progressive loss of retinal
ganglion cells (RGCs). Previous studies have shown that application of a specific α7 nicotinic
acetylcholine receptor agonist, PNU-282987 (PNU), onto the murine retina induces neurogenesis
of numerous retinal cell types, including RGCs. The aim of this study is to characterize the shortterm and long-term effects of PNU in a glaucoma model. The effects of PNU were analyzed in a
DBA/2J mouse model that auto-induces a glaucoma-like condition in adulthood. These mice
manifest an elevated intraocular pressure (IOP) starting at 6 months, followed by loss of RGCs.
To assess short-term regenerative effects, PNU treatment was applied daily as eye drops for 2
weeks to DBA/2J mice at various ages (3, 6, and 10 months). To assess the effects of early
treatment, a chronic early treatment group began receiving PNU at either 3 or 6 months and
received weekly treatment until the animals reached 10 months. An acute early treatment group
received two-week daily treatment at either 3 or 6 months, then no further treatment until they
reached 10 months. Following treatment, retinas were removed, fixed, processed using IHC
procedures, and RGC regeneration was assessed and compared. Results showed a 29% loss of
RGCs by 10 months of age in this DBA/2J colony. Two-week application of PNU induced a
significant 21% increase in RGCs across all time points. Chronic early treatment produced a
similarly significant increase in RGCs while acute early treatment had no effect on RGC
numbers. 2-week treatment with PNU, as well as chronic long-term treatment, induced a
significant increase in the number of RGCs in the DBA/2J retina, counteracting the effects of the
DBA/2J genetic glaucoma-like condition. These results suggest the future clinical potential of
PNU in the treatment of degenerative retinal diseases.
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CHAPTER I
INTRODUCTION
Hypothesis and specific aims
The goal of this study is to test the ability of PNU-282987 to reverse the loss of retinal
ganglion cells that is generally associated with glaucoma using the DBA/2J genetic mouse
glaucoma model. These studies were also designed to determine whether early treatment with
PNU-282987 can prevent the degenerative effects of glaucoma in the genetic mouse model. Two
specific aims were designed to test these goals:
Specific Aim 1: To determine if acute treatment with the specific α7 nicotinic acetylcholine
receptor agonist, PNU-282987, reverses the loss of retinal ganglion cells in the DBA/2J genetic
mouse glaucoma model.
Specifically, PNU-282987 was administered daily for two weeks to groups of 3-month-old, 6month-old, and 10-month-old animals to determine the number of retinal ganglion cells in
DBA/2J retinas compared to wild-type controls.
Specific Aim 2: To determine if early treatment with the specific α7 nicotinic acetylcholine
receptor agonist can reverse genetic retinal degeneration associated with the DBA/2J model of
glaucoma.
Specifically, both repeated and acute early treatment were assessed in this study. In the
repeated early treatment experiments, administration of PNU-282987 as eye drops began at an
early age, before the onset of the disease, and was administered once per week until the animal
reached 10 months of age. In the acute early treatment experiments, administration of PNU282987 similarly began before the onset of the disease, but the animals received daily
treatment for two weeks and then received no further treatment until the animal reached 10
months of age.
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The hypothesis tested in this thesis is that repeated treatment with the specific α7 nAChR
agonist, PNU-282987, will significantly reduce the loss of retinal ganglion cells typically
associated with the DBA/2J model of glaucoma.
The following paragraphs include an introduction to the functioning of the eye, an
explanation of the different types of glaucoma, the DBA/2J mouse model of glaucoma, and the
previous studies performed in this lab that have examined the regenerative potential of PNU282987, a specific α7 nicotinic acetylcholine receptor agonist.
Anatomy of the vertebrate eye
These studies have been conducted using the retinas from adult mice eyes. The eye is a
complex sensory organ specialized to capture and focus light from the surrounding environment
and convert it into an image that the brain interprets as vision. Anatomically, the eye is made up
of three different layers. The outermost fibrous layer is a tough, white, opaque tissue called the
sclera. At the most anterior surface of the eye, the sclera changes to a clear, thin, dome-shaped
tissue called the cornea. Light passes through the cornea and is refracted, providing the initial
step of focusing light onto the retina.
Once the light passes through the cornea and is refracted, the light passes through the
pupil, which is a center hole surrounded by the iris muscle. The iris is a sphincter muscle that
constricts or dilates to regulate the amount of light that enters into the circular pupil. Next, the
light passes through the lens, which focuses the light onto the back of the eye. The lens is a
transparent biconvex structure that is able to change its shape to change the focal length of the
eye in order to be able to focus on objects at various distances. The lens is able to change shape
because it is attached to the ciliary muscle, a circular muscle that can contract to stretch the lens
and relax to flatten the lens. Through this mechanism, the eye is able to accommodate light from
different distances and properly focus them on the retina (Sherwood, 2011)
The middle layer of the eye is the choroid. This is the main vascular layer of the eye that
provides the eye with blood, oxygen, and nutrients. At the back of the eye lies the innermost
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tissue layer, or neural layer, called the retina. The retina lines the inside of the back of the eye
and contains light sensitive cells that are able to convert photons of light into an electrical signal
that can be interpreted by the brain as an image (Sherwood, 2011).

Figure 1. Gross Anatomy of the Eye. The most relevant structures of the eye to this study are the anterior
space, posterior space, and the retina. The aqueous humor is a clear fluid located in the anterior and
posterior spaces of the eye. In glaucoma, intraocular pressure within these spaces builds up when aqueous
humor is unable to drain. A high intraocular pressure is a risk factor for loss of retinal cells. This study
will primarily focus on the retina, the nervous tissue located at the back of the eye, and the associated
glaucomatous damage. Image created using BioRender.

The eye can also be divided into three chambers: the anterior chamber, the posterior
chamber, and the vitreous chamber. The anterior chamber is located between the cornea and the
iris, the posterior chamber is located between the iris and the lens, and the vitreous chamber is
located between the lens and the retina. The eye also contains two fluids that give support and
nutrients to the rest of the eye: the vitreous humor and the aqueous humor. One of these fluids,
the vitreous humor, is a transparent fluid that fills the vitreous chamber, the space between the
lens and the retina. The vitreous humor helps maintain the structure of the eye and keep the
3

retina in place. The other fluid, the aqueous humor is a transparent, water-like fluid located in
both the anterior and posterior chambers of the eye. It is produced from the ciliary body, a
structure that supports the lens, and drains out of the eye through the trabecular meshwork,
which is located in the anterior chamber of the eye at the base of the cornea near the ciliary
bodies.
One primary function of the aqueous humor is to maintain intraocular pressure, which
helps maintain the shape of the eye and keep the walls of the eyeball taut. A normal intraocular
pressure is maintained by a balance between the amount of aqueous humor that is produced by
the ciliary bodies and the amount that is drained out of the trabecular meshwork. The trabecular
meshwork is a spongy tissue that allows fluid to drain into Schlemm’s canal, which is a
lymphatic-like vessel that delivers fluid into the episcleral blood vessels. If the trabecular
meshwork or Schlemm’s canal is blocked or damaged, it can prevent the drainage of aqueous
humor and cause an excessive buildup of intraocular pressure within the eye (Llobet et al., 2003).
Retinal anatomy
The buildup of intraocular pressure within the eye can lead to death of retinal ganglion
cells (RGCs), a retinal neuron that conveys visual information to the brain. The retina is the
neural layer at the back of the eye that converts photons of light into a neural signal that the brain
can form into a visual image, a process known as phototransduction. The process of
phototransduction involves five different types of retinal neurons: photoreceptors, bipolar cells,
ganglion cells, horizontal cells, and amacrine cells. The retina can be divided up into three main
nuclear layers, which contain the cell bodies of all five retinal neuron types: the outer nuclear
layer (ONL), the inner nuclear layer (INL), and the ganglion cell layer (GCL).
Outer nuclear layer:
The outer nuclear layer contains the photoreceptors. This layer is the most posterior layer
but is the first step in the process of phototransduction. As light enters the eye, it is absorbed by
the rhodopsin molecules on the photoreceptor and causes the photoreceptors to hyperpolarize.
4

There are two different types of photoreceptors: rods and cones. Rods are adapted for low light
environments and play little role in color vision whereas cones are adapted for high light
environments and are used for color perception. Rods are most concentrated at the outer edges of
the retina while cones are more numerous near the center of the visual field. Cones are especially
concentrated in a region of the retina called the fovea, located at the center of the macula.
There are three different types of cone photoreceptors, red, green, and blue, each of
which can sense a different wavelength of light. In the dark, photoreceptors release a constant
stream of the neurotransmitter glutamate on the bipolar cells. When light activates the
photoreceptor, phototransduction occurs leading to photoreceptor hyperpolarization, which
prevents the release of the photoreceptor neurotransmitter, glutamate, onto the bipolar cells.
Bipolar cells respond to glutamate with a hyperpolarization or a depolarization depending on the
glutamate receptors found in the bipolar cell dendrites. Depolarization of bipolar cells sends the
electrical signal to the retinal ganglion cells.
Inner nuclear layer:
The next layer of the retina is the inner nuclear layer (INL), which consists of the bipolar
cells, horizontal cells and amacrine cells. Bipolar cells are responsible for transmitting the
electrical signal from the photoreceptors to the ganglion cells. Like photoreceptors, bipolar cells
release the neurotransmitter, glutamate, onto retinal ganglion cells, where it has an excitatory
effect and depolarizes the ganglion cells. The other two types of retinal neurons in the INL,
horizontal cells and amacrine cells, play a regulatory role on the signal being transmitted
between the photoreceptors, bipolar cells, and ganglion cells.
The retinal ganglion cell layer makes up the third nuclear layer of the retina (GCL).
Retinal ganglion cells are responsible for processing visual information that occurs within the
retina, such as stimulus intensity, contrast detection, color detection, and directional selectivity
(Yu et al., 2013). The axons of the retinal ganglion cells form the optic nerve and carry the
electrical signal into the brain, where they synapse at the lateral geniculate nucleus (LGN) and
eventually travel to the occipital lobe for final processing.
5

There are over a dozen different subtypes of retinal ganglion cells, which vary in size,
connectivity, and function, but this study does not differentiate between the different subtypes, so
they will not be discussed here. Retinal ganglion cells have been shown to contain α7 nicotinic
acetylcholine receptors, which bind to acetylcholine, released endogenously within the retina by
starburst amacrine cells. These acetylcholine receptors are important to the normal functioning of
the retina because it affects the response properties of many retinal ganglion cells (Strang et al.,
2005).

Figure 2. The Layers of the Mammalian Retina. Light is initially absorbed at the photoreceptors and the
signal is transmitted through the bipolar cells, retinal ganglion cells, and travels down the optic nerve to
the occipital lobe. The retinal pigment epithelium plays an important role in the mechanism of
regeneration. This study focuses primarily on the retinal ganglion cell layer. Image created using
BioRender.

α7 receptors are also located elsewhere in the brain, with the highest concentrations in the
hippocampus, the thalamic reticular nucleus, as well as the lateral and medial geniculate nuclei
(Tregellas & Wylie, 2019). Numerous studies have linked nicotinic dysfunction, particularly
6

involving α7 receptors, to schizophrenia. In the reticular nucleus of the thalamus, alpha7 nAChR
expression is decreased in subjects with schizophrenia (Court et al., 1999). Thus, numerous α7
nicotinic acetylcholine receptor agonists have been tested as possible treatments for
schizophrenia (Deutsch et al., 2013; Martin & Freedman, 2007). The α7 agonist used in this
study was originally developed for this very purpose.
Glaucoma
Normal functioning of the retina can be disrupted by neurodegenerative diseases such as
glaucoma. Glaucoma is a family of degenerative retinal diseases characterized by progressive
loss of retinal ganglion cells (RGCs) within the retina, leading to vision loss. In humans, there
are many different types of glaucoma including open-angle glaucoma, angle-closure glaucoma,
normal tension glaucoma, and pigmentary glaucoma. Each form of glaucoma has a different
underlying pathophysiology but all result in the progressive death of retinal ganglion cells
(Weinreb et al., 2014).
Open-angle glaucoma, the most common type, is caused by the slow clogging of the
drainage canals, the trabecular meshwork, in the anterior chamber of the eye. The blockage of
the trabecular meshwork prevents the proper drainage of the aqueous humor, which results in an
increased intra-ocular pressure. The cause of the clogging of the trabecular meshwork is not well
understood in open-angle glaucoma (Kwon et al., 2009). An increase in intraocular pressure in
the anterior and posterior chamber of the eye is thought to put pressure on the lens and push it
inward into the vitreous chamber. This leads to an increase in pressure within the vitreous
chamber that causes damage to the sensitive ganglion cells of the retina. This type of glaucoma is
called open-angle glaucoma because the angle between the iris and the cornea is open and wide
(obtuse). The condition develops very slowly and remains a lifelong condition. There is currently
no cure for open-angle glaucoma.
Angle-closure glaucoma on the other hand, is caused by the blockage of the drainage
canals. This type of glaucoma is called angle-closure glaucoma because there is a closed or
narrow angle between the iris and the cornea. It is this narrow angle that causes the closing off of
7

the trabecular meshwork (Weinreb et al., 2014). While both open-angle and angle-closure
glaucoma are caused by the blockage of the trabecular meshwork, the blockage in angle-closure
glaucoma is the result of the narrow angle between the iris and the cornea, whereas the cause of
the blockage in open-angle glaucoma is less clear. The other main difference between the two is
that angle-closure glaucoma develops very quickly. Often, the onset is acute and requires
immediate medical attention.

Figure 3. Open-Angle vs. Angle-Closure Glaucoma. In a non-glaucomatous retina, aqueous humor is
produced by the ciliary body and drains out of the eye via the trabecular network and the drainage canal.
In open-angle glaucoma, the flow of aqueous humor is not impeded, but drainage is prevented at the
trabecular meshwork, leading to a buildup of intraocular pressure. In angle-closure glaucoma, the path of
the aqueous humor is physically blocked, leading to a sudden and dangerous buildup of pressure. Image
created using BioRender.

Normal-tension glaucoma, like the other forms of glaucoma, result in the death of retinal
ganglion cells, but unlike other forms of glaucoma, the intra-ocular pressure remains normal. The
cause of the optic nerve damage despite a normal intra-ocular pressure is currently unclear
(Trivli et al., 2019).
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Pigmentary glaucoma is another form of glaucoma also caused by the blockage of the
trabecular meshwork. In this case, the blockage is caused by pigment dispersion syndrome,
which is a condition that happens when pigment rubs off of the back of the iris of the eye and is
deposited in the trabecular meshwork, where the fluid drains out. The loose pigment blocks off
the trabecular meshwork and leads to a buildup of intraocular meshwork. The DBA/2J mice used
in this study present a form of pigmentary glaucoma (Scuderi et al., 2019).

DBA/2J mice
DBA/2J mice are an inbred strain of mouse characterized by a degenerative glaucomalike condition that develops around 6-9 months of age. This degenerative disease closely mimics
human pigmentary glaucoma and is similarly characterized by a progressive increase in
intraocular pressure that leads to retinal ganglion cell loss. Thus DBA/2J mice are an ideal model
for studying genetic glaucoma in humans. Similar to human pigmentary glaucoma, the pathology
is caused by the blockage of the trabecular meshwork by pigment molecules from the iris. The
primary difference is that in human pigmentary glaucoma, the pigment is rubbed off of the iris
by the fibers supporting the lens, whereas in the DBA/2J model, the pigment is thought to fall
out of the iris due to genetic defects in melanosome structure and pigment synthesis. In addition
to their visual pathology, DBA/2J mice are also susceptible to developing atherosclerotic aortic
lesions, high-frequency hearing loss, and audiogenic seizures, although these characteristics are
unrelated to the current study.
The DBA/2J visual pathology is primarily linked to mutations in two separate genes:
Tyrp1b and Gpnmb. Tyrp1b is a gene that encodes for tyrosinase-related protein 1, which is
located in melanocytes. Tyrosinase-related protein 1 is involved in the production of melanin,
although its exact functions are unclear. Studies suggest that this enzyme may help stabilize
tyrosinase, which is the enzyme responsible for the first step in melanin production. Tyrosinaserelated protein 1 may also help determine the shape of melanosomes, which are the structures in
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melanocytes where melanin is produced. The mutant allele is “isa”, which stands for iris stromal
atrophy. “Isa” is referring to the phenotype.
Gpnmb is a transmembrane glycoprotein thought to be important for melanin
biosynthesis and the development of the retinal pigment epithelium and iris. In DBA/2J mice,
the Gpnmb gene carries a stop codon mutation (GpnmbR150X). The mutant allele is R150X,
which indicates a C to T substitution that results in a nonsense mutation, Arg150stop. Since
both Tyrp1band GpnmbR150X gene products are associated with melanosomes, it has been
proposed that the initial pathology of anterior chamber disease in these mice is caused by an
abnormality in iris pigment synthesis and melanosome structure (S. W. M. John, 2005). In this
model, cytotoxic byproducts from abnormal pigment synthesis may eventually leak out of
structurally compromised melanosomes. This hypothesis is supported by evidence that DBA/2J
mice engineered with tyrosinase mutations, making them albino, exhibit no disease phenotype
(Chang et al., 1999).
Mice homozygous for both mutant genes exhibit anterior chamber pathology
characterized by pigment dispersion and iris stromal atrophy, while substitution of wild-type
alleles on the DBA genetic background prevents this (Howell et al., 2007). A distinguishing
feature of the disease is the development of iris illumination defects associated with the loss of
pigment granules. As the pigment is dispersed into the anterior chamber, it accumulates in the
mouse trabecular meshwork leading to the formation of synechiae, blockage of the drainage
structures, and the elevation of intraocular pressure.
Both mutations have been shown to be necessary to produce the visual pathology. Recent
examination of a DBA/2 substrain from a European colony (DBA/2J-Rj), for example, show that
mice with a variant of the Gpnmb gene develop typical anterior chamber pathology, elevated
IOP, but no clear neurodegenerative phenotype (Scholz et al., 2008). This study is suggestive
that Gpnmb may also play a role in the ganglion cell susceptibility to elevated IOP, but it should
be noted that this particular substrain of the DBA/2 mouse has not been fully characterized for
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other genetic differences that may have arisen in this isolated colony

Figure 4. Anatomy of a Melanocyte. Melanocytes are responsible for the production of the pigment
melanin throughout the body, including the retina. Newly synthesized melanin is packaged in transport
organelles called melanosomes and transported out of the melanocyte. Both the Gpnmb and Tyrp1b
mutations in DBA/2J mice affect the production of melanin in melanocytes and lead to pigment
dispersion syndrome. Image created using BioRender.

Generally, however, iris disease begins to manifest by 6-8 months of age in DBA/2J
mice. Shortly thereafter, mice can exhibit increased IOPs that exceed 3 standard deviations over
the mean IOP for younger animals (Libby et al., 2005). In studies involving large numbers of
animals at different ages, the majority of mice between the ages of 8 and 13 months have
elevated IOPs. The first evidence of glaucoma in these animals occurs as damage to the optic
nerve. Independent studies show that aging mice exhibit axonal loss and optic nerve gliosis
shortly after the onset of elevated IOP, around 8 months of age (Libby et al., 2005; Schlamp et
al., 2006). Overall, the mechanism of axonal loss in the optic nerve appears more similar to the
“die-back” pattern, where the axons degenerate in a retrograde direction (Schlamp et al., 2006),
11

as opposed to more classic Wallerian degeneration, where damaged axons degenerate at multiple
points simultaneously along their length (Beirowski et al., 2005). This period of axonal
degeneration coincides with compromised retrograde axonal transport (Buckingham et al., 2008;
Jakobs et al., 2005), which precedes the degeneration of the ganglion cell soma in the retina.
Ganglion cell soma loss is first evident in glaucomatous DBA/2J mice at or near the time
when animals are clearly exhibiting optic nerve disease, but the majority of animals exhibit
retinal degeneration by approximately 10–11 months of age (Schlamp et al., 2006). Several
studies have examined the process of ganglion cell death in these mice using both electron
microscopic and biochemical techniques, indicating that apoptosis is the most likely mechanism
of soma loss in these mice (Libby et al., 2005; Schuettauf et al., 2004). Peak DNA fragmentation,
monitored by TUNEL-staining and intercalating dyes, occurs during the period of 10–11 months,
consistent with other methodologies that simply monitor the presence or the absence of ganglion
cells (Libby et al., 2005).
Select studies have used DBA/2J mice to investigate neuroprotection, but this study is
unique in that it investigates regeneration in the DBA/2J model rather than neuroprotection. A
2007 study by Zhong et al.(Zhang et al., 2016) used DBA/2J mice to test the efficacy of
erythropoietin as a neuroprotective agent. They found that treatment with erythropoietin
prevented significant retinal ganglion cell loss, indicating a neuroprotective effect. Neuroglobin,
a mitochondrial protein, has also been tested in DBA mice and found to have a neuroprotective
effect (Cwerman-Thibault et al., 2017). Regeneration differs from neuroprotection in that new
cells are being produced during regeneration, whereas neuroprotection prevents apoptosis in the
existing cells by triggering a specific cell survival pathway (Asomugha et al., 2009).

PNU-282987
PNU-282987 is a highly selective α7 nicotinic acetylcholine receptor agonist that was
first developed by the Pharmacia and Upjohn Company and is used extensively in this study as a
neurogenic agent (Bodnar et al., 2005; Hajós et al., 2005; Taly et al., 2009; Walker et al., 2006;
12

Webster et al., 2017). α7 receptors are located throughout the body including the retina, brain,
spleen, and lymphocytes. Within the eye, only four different cell types are known to contain α7
receptors: retinal pigment epithelial (RPE) cells, bipolar cells, ganglion cells, and certain types of
amacrine cells (Dmitrieva et al., 2007; Hall et al., 2019). Numerous studies have shown that α7
receptors are not present on Müller glia cells (Stanchfield et al., 2020; Webster et al., 2019).
Structurally, nicotinic acetylcholine receptors are composed of five subunits arranged
symmetrically around a central pore. The receptor can either be homomeric, meaning it is
composed of only one type of subunit, or heteromeric, which is composed of a combination of
different subunit types. The α7 nAChR is homomeric and is composed of five α7 subunits.
Nicotinic acetylcholine receptors are ionotropic receptors, meaning they are directly
linked to ion channels, although some evidence shows that they can use second messengers in
some cases (Kabbani et al., 2013). Activation of the receptor opens the channel and allows
calcium to flow into the cell.
Previous Research Using PNU-282987
Previous studies in this lab have used this specific α7 nAChR agonist in a surgical model
of glaucoma to study its neuroprotective effects where it was applied directly into the vitreal
chamber (Cooley-Themm et al., 2017; Iwamoto et al., 2014; Mata et al., 2015). Neuroprotection
is any intervention that prevents optic nerve damage or retinal ganglion cell death. Glaucoma
was surgically induced by injecting hypertonic saline into the episcleral vein of the eye. These
injections cause scarring of the trabecular meshwork system to reduce outflow of the aqueous
humor in the anterior chamber of the eye. As a result, there is an increase in intraocular pressure
within one month of injection that leads to significant loss of retinal ganglion cells that mimics
the effect of glaucoma.
Results indicated that intravitreal injection of PNU-282987 into the eye before inducing
retinal ganglion cell death had a neuroprotective effect and showed a significant decrease in the
number of ganglion cells that underwent apoptosis (Iwamoto et al., 2014). When injected into the
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vitreal chamber, PNU-282987 acts directly on α7 nAChRs on retinal ganglion cells to stimulate
the IP3-Akt-Bcl2 neuroprotective pathway (Asomugha et al., 2009; Cooley-Themm et al., 2017;
Iwamoto et al., 2014).
However, if PNU-282987 is applied as eye drops in vivo, it induces regeneration of new
retinal neurons in adult mice (Webster et al., 2017, 2019). Specifically, when applied as eye
drops, evidence has been provided that PNU-282987 binds to α7 nAChRs on the retinal pigment
epithelium to release signaling molecules that cause de-differentiation of Müller glia (Webster et
al., 2019). Müller glia are the most common type of glia cell in the retina and span the entire
length of the retina, with their cell bodies located in the inner nuclear layer. Their main role is to
maintain the homeostatic stability of retinal cells. They do this by controlling the contents of the
extracellular fluid, neurotransmitter uptake, as well as mechanical support of the neural retina
(Goldman, 2014; Reichenbach & Bringmann, 2013).
Müller glia cells were found to de-differentiate to progenitor cells after eye drop
application of PNU-282987, which later differentiate into several types of retinal neurons
including photoreceptors, cholinergic amacrine cells, and retinal ganglion cells (Webster et al.,
2017, 2019). The genes involved in Müller glia de-differentiation after PNU-282987 treatment
have been investigated using mRNA sequencing and qRT-PCR (Stanchfield et al., 2020). These
studies demonstrated that activation of the HB-EGF/Ascl1/Lin28a signaling pathway in Müller
glia after introduction of signaling molecules released from RPE cells leads to the genesis of
Müller-derived RPCs (Stanchfield et al., 2020).
Regeneration differs from neuroprotection in that new cells are created, whereas
neuroprotection prevents the deaths of the existing cells but does not produce new cells.
Regeneration occurs naturally in many non-mammals, such as zebrafish and chick, in response to
injury but this does not occur in mammals (Wan & Goldman, 2016; Wilken & Reh, 2016). This
regenerative mechanism has been extensively studied in both of these animal models. In
zebrafish, like in the previous rodent studies from this lab, new retinal progenitor cells arise from
Müller glia, which can differentiate into most cell types within the retina.
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As a result, in this study, acute and repeated eye drop treatment with PNU-282987 was
used to reverse the loss of retinal ganglion cells in a genetic DBA/2J mouse model of glaucoma.
Results indicated that two-week daily treatment with PNU-282987 produced significant numbers
of BrdU+ cells, which was enough to offset the loss of retinal ganglion cells caused by the
glaucomatous condition in the DBA/2J mice. To determine if early treatment with PNU-282987
could offset glaucomatous damage in the DBA/2J mice, PNU-282987 was administered as eye
drops once per week starting at an early age and continued until the animal reached 10 months of
age. Results indicated that once per week treatment with PNU-282987 was sufficient to offset
the loss of retinal ganglion cells in DBA/2J mice. The main implication of this study is the
potential use of PNU-282987 as an effective treatment for glaucoma in humans.
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Abstract
Previous studies have shown that eye drop application of the selective α7 nicotinic
acetylcholine receptor agonist, PNU-282987, induces neurogenesis of RGCs in adult wild-type
rodents. This study was designed to test the hypothesis that PNU-282987 reverses the loss of
RGCs associated with glaucoma. A DBA/2J mouse model that auto-induces a glaucoma-like
condition in adulthood was used for these studies. Short-term effects using PNU-282987 and
BrdU eye drop treatments were examined, as well as the effects of early treatment and the effects
in a chronic early treatment group in DBA/2J mice aged 3, 6 and 10 months. With and without
treatment, retinas were removed, fixed, immunostained and RGC counts were assessed. IOP
measurements were obtained weekly using a Tonolab tonometer. Results showed an average
typical loss of BrdU positive RGCs by 29% by 10 months of age in this DBA/2J colony
corresponding with a significant increase in IOP. However, the two-week short-term application
of PNU-282987 and BrdU induced a significant 21% increase in RGCs for DBA/2J mice at all
ages. Chronic early PNU-282987 treatment produced a similarly significant increase in RGCs,
while acute early treatment had no effect on RGC numbers. IOP measurements were not affected
with PNU-282987 treatment. These studies demonstrated that 2-week treatment with PNU282987, as well as chronic long-term treatment, induced a significant increase in the number of
RGCs in the DBA/2J retina, counteracting the effects of the DBA/2J genetic glaucoma-like
condition. These results suggest a potential future treatment of degenerative retinal diseases with
PNU-282987.
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Introduction
Glaucoma is a degenerative retinal disease characterized by loss of vision due to
progressive death of Retinal Ganglion Cells (RGCs) and is the second leading cause of
irreversible vision loss worldwide (Rossetti et al., 2015). One of the primary risk factors for
glaucoma is increased Intraocular Pressure (IOP), which is associated with death of RGCs.
Presently, there is no cure for glaucoma and the loss of RGCs and their axons in the optic nerve
is irreversible in humans (Buckingham et al., 2008). All current treatments are aimed at
decreasing IOP to prevent RGC death (Bucolo et al., 2015). Unfortunately, these treatments can
prevent further progression of the disease but cannot reverse any loss of vision. However,
neuroprotection or regeneration of RGCs could potentially reverse the effects of glaucoma. Here,
results are presented to provide evidence of BrdU positive RGCs after PNU-282987 eye drop
treatment in adult animals using a DBA/2J genetic mouse model of glaucoma.
Recent studies from this lab have shown that neuroprotection or robust regeneration can
be induced in the retinas of adult mammals when treated with a specific α7 nicotinic
acetylcholine receptor agonist, PNU-282987 depending on the type of treatment (Cooley-Themm
et al., 2017; Iwamoto et al., 2014; Mata et al., 2015; Webster et al., 2017, 2019). In
neuroprotective studies, PNU-282987 was shown to provide RGC neuroprotection against
induced glaucoma-like conditions when it was intraocularly injected (Cooley-Themm et al.,
2017; Iwamoto et al., 2014; Mata et al., 2015). PNU-28987 was found to bind to alpha7 nAChRs
on RGCs and mimicked the physiological neuroprotective effect of ACh typically released from
starburst amacrine cells (Cooley-Themm et al., 2017). When injected intraocularly, PNU-282987
provided neuroprotection against the significant loss of RGCs that occurred in the GCL after
inducing glaucoma-like conditions (Cooley-Themm et al., 2017).
Adult mammalian retinal cells do not typically regenerate, but regeneration does occur
naturally in many non-mammals, such as zebrafish and chick, in response to injury (Wan &
Goldman, 2016; Wilken & Reh, 2016). Recent studies from this lab have demonstrated that if
PNU-282987 is applied as eye drops, it induces robust regeneration of new neurons in all layers
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of the retina without inducing an injury. Specifically, when applied as eye drops, PNU-282987
acts on alpha-7 nAChRs on the RPE to induce release of signaling molecules that cause dedifferentiation of Müller Glia (MG) cells in adult mice (Webster et al., 2017, 2019). Specifically,
PNU-282987 has the ability to cause MG to generate Müller-Derived Progenitor Cells (MDPCs)
and generate multiple types of new differentiated neurons in adult mammalian retinas (Webster
et al., 2017, 2019). The neurogenic response of PNU-282987 in the adult murine retina is robust
and the division of the MG into progenitor cells follows a similar pattern to that seen in zebrafish
regeneration (Webster et al., 2017, 2019). In mRNA sequencing studies, RNAseq was performed
on MG following contact with RPE cells treated with PNU-282987. Up- or down-regulated
genes were compared with published literature of MG dedifferentiation that occurs in lower
vertebrate regeneration or with transcript profiles during early mammalian development. These
studies provided evidence that the HB-EGF/Ascl1/Lin28a signaling pathway was involved in
MG dedifferentiation to retinal progenitor cells (Stanchfield et al., 2020). RNA-seq results were
verified using qRT-PCR and using immunocytochemistry, the presence of retinal progenitor
markers OTX2, Nestin and VSX2 in MG were identified 48 hours post treatment with PNU282987 treated RPE supernatant (Stanchfield et al., 2020). However, it is unknown if PNU282987 can regenerate or provide neuroprotection to neurons lost to retinal damage due to
genetic disease.
In this study, PNU-282987 was analyzed in an in vivo DBA/2J mouse model. DBA/2J
mice are an inbred strain of mouse characterized by a degenerative glaucoma-like condition that
develops around 6-9 months of age (Schuettauf et al., 2004). This degenerative disease closely
mimics human pigmentary glaucoma and is similarly characterized by a progressive increase in
intraocular pressure that leads to retinal ganglion cell loss (Buckingham et al., 2008; Wang &
Dong, 2016). Thus DBA/2J mice are an ideal model for studying genetic glaucoma in humans.
DBA/2J mice are homozygous for mutations in two separate genes. One mutation is found on the
b allele of tyrosine related protein (Tyrp1b), which encodes a melanosomal protein (Anderson et
al., 2002; Chang et al., 1999). The second mutant gene encodes Gpnmb, a transmembrane
glycoprotein located within many cellular structures (Anderson et al., 2002; Howell et al., 2007).
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A distinguishing feature of the disease is loss of pigment granules within the iris. These pigment
granules accumulate in the trabecular meshwork of the anterior chamber and block the drainage
structures, which results in an elevated intraocular pressure (S. W. John et al., 1998; Mckinnon et
al., 2009). The rise in IOP in DBA/2J mice is often reported by 6-9 months of age (Anderson et
al., 2008; Bosco et al., 2008; Fernández-Sánchez et al., 2014; Goldblum & Mittag, 2002; Scholz
et al., 2008; Turner et al., 2017). and DBA/2J mice experience axonal loss and optic nerve
damage shortly after the onset of elevated IOP (Libby et al., 2005; Schlamp et al., 2006). Thus
far, most studies involving DBA/2J mice have focused on neuroprotection, not regeneration. For
example, erythropoietin and neuroglobin have both been shown to have a neuroprotective effect
against the onset of the glaucoma-like disease in DBA/2J mice (Cwerman-Thibault et al., 2017;
Zhong et al., 2007). However, in this study, PNU-282987 was applied as eye drops to examine
its effect in a genetic model of glaucoma. Specifically, these studies will provide evidence that
early treatment with PNU-28297 can prevent or reverse the progressive loss of RGCs associated
with the disease in adult DBA/2J mice.
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Materials and Methods
Animals
Adult DBA/2J mice (both sexes; aged between 3 and 12 months) were used for these studies and
were kept in Western Michigan University’s (WMU) animal facility. The mice were obtained
from Jackson laboratories. SVJ-129 wildtype mice were used as a control in one experiment. All
animals were cared for in accordance with the approved guidelines of the Institutional Animal
Care and Use Committee (IACUC) of WMU.
Intraocular Pressure (IOP) measurement
Intraocular pressure measurements were taken using an Icare Tonolab tonometer.
Because IOP measurements tend to fluctuate throughout the day, measurements were taken at the
same time each evening. IOP measurements were obtained two times each week from awake
mice. Briefly, animals were removed from their home cages and held gently. A handheld
Tonolab. tonometer was then applied to the cornea of experimental eyes to obtain IOP
measurements before and after various eye drop treatments with PNU-282987. On each
measurement day, 3 IOP measurements were obtained from each experimental animal and
averaged. This was performed for between 5 and 20 animals depending on the designated end
time point specified by the experimental protocols.
Experimental design
Experiments were designed to determine whether the α7 nAChR agonist, PNU-282987
produced proliferation in the genetic mouse model. Three different age groups of DBA/2J mice
were treated daily for 2 weeks with PNU-282987: 3 months old, 6 months old, and 10 months
old. These ages were chosen to get a sampling of the different stages of the disease. 3-month-old
animals have reached adulthood but have yet to develop the disease and thus have lost minimal
RGCs. At 6 months old, the disease is in its early stages and at 10 months, the disease is fully
developed. Five animals from each age group receive 2 weeks of treatment with PNU-282987,
Their retinas were then removed and RGC survival was assessed.
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Additional experiments were designed to examine the effects of early treatment with
PNU-282987. The prevention of the disease with early treatment of PNU-282987 could not be
shown in the previous induced surgical model of glaucoma. The use of the DBA/2J genetic
model allows a unique opportunity to treat the animal in anticipation of the onset of the disease.
In this experiment, DBA/2J mice received treatment before they developed their characteristic
glaucoma-like condition, to determine if it would prevent the progression of the disease. There
were two treatment conditions: chronic early treatment and acute early treatment. In the chronic
early treatment studies, animals started receiving once weekly PNU treatment at an early age that
continued until the animals reached 10 months of age. There were two time points within this
group: 3 months old and 6 months old. The 3-month-old group began treatment at 3 months of
age and the 6-month-old group began treatment at 6 months of age. Five mice at each time point
were assessed. Each group continued receiving PNU once per week until they were 10 months
old. At 10 months of age, their retinas were removed and RGC survival was assessed.
The acute early treatment animals received two weeks of PNU treatment before the onset
of the disease. Following that two weeks, the animals received no further treatment and were left
alone until they were 10 months old; at which point their retinas were removed and RGC
survival was assessed. 3 and 6-month old mice were used for this study. Five animals at each
time point received 2 weeks of PNU treatment at 3 or 6 months old and then left, with no further
treatment, until they were 10 months old.
Eye drop treatment and retina preparation
Both eyes of each experimental animal were treated once daily with PBS eye drops
containing 1 mg/mL BrdU and 1 mM PNU-282987. The concentration of PNU-282987 and
BrdU used in eye drop experiments in rodents was previously established in dose response
studies and the dosage that produced maximal effects was used (Linn et al., 2018; Webster et al.,
2017, 2019). Animals in the short-term treatment groups received this treatment once daily for 2
weeks while the long-term treatment animals received treatment once weekly for 3-6 months.
Control animals received drops containing only PBS and 1 mg/mL BrdU. Details of the eye drop
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treatment are described in Linn et al. (Linn et al., 2018). At specific times following the start of
treatment, mice were euthanized. The eyes were subsequently removed, and retinas were
excised, flat-mounted, and fixed in 4% paraformaldehyde overnight at 4ºC (Iwamoto et al., 2014;
Mata et al., 2015).
Immunohistochemistry
Following fixation, retinas were labeled with primary antibodies including sheep antiBrdU (7.5 μL/mL, Abcam ab1894, Cambridge, UK) and rat anti-Thy1.2 (1:200, Abcam ab
218775). Thy-1.2 is a cell surface protein used as a marker for RGCs in mice. BrdU is used as a
marker for cell cycle reentry. For BrdU staining, antigen retrieval was done as in Webster et al.
(Webster et al., 2019). Retinas were blocked in PBS containing 1% Triton X-100 and 1% bovine
serum. Retinas were incubated in primary antibodies overnight at room temperature in PBS
containing 1% bovine serum and 1% goat serum, rinsed in PBS and incubated overnight with
appropriate Alexa Fluor conjugated secondary antibodies (1:300, Life Technologies) diluted in
PBS without serum. Nuclei were stained with DAPI.
Cell counting and normalization
Stained retinas were then flat mounted on slides and visualized using a Nikon C2+
scanning laser confocal microscope. Four images of each flat-mounted retina were taken from
each of four quadrants of the retina. Each image was taken 4 mm from the optic nerve head
(Iwamoto et al., 2014; Mata et al., 2015). To quantify the flat mounts, a fixed 200×200 μm2 grid
was applied to all images and the Thy1.2-positive RGCs within the grid for each retinal quadrant
were counted. The RGC counts from the four quadrants were averaged together according to the
procedure outlined in Mata et al. (Mata et al., 2015). Webster et al. (Webster et al., 2017). and
Cooley-Themm et al. (Cooley-Themm et al., 2017). This represented an “N” of 1 for flatmounted retinas and “N”s of 5 were obtained for each experimental condition.
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Statistical analysis
Statistical analysis was performed on all normalized data using an analysis of variance
(ANOVA) as well as Tukey post-hoc analysis. P<0.01 was considered statistically different.

23

Results and Discussion
Progression of glaucoma-like RGC loss in DBA/2J mice
Experiments were designed to quantify the loss of RGCs in DBA/2J mice. (Figure 5)
shows confocal microscope images obtained from untreated DBA/2J retinas of different ages.
The retinas were fixed overnight in 4% paraformaldehyde and flat mounted with the retinal
ganglion cell layer facing up. After thorough rinsing, the retinas were immunostained using
antibodies against Thy-1.2, a marker for RGCs. RGCs were counted and averaged from 5
different animals under different age groups. (Figure 5A) illustrates an image of a DBA/2J retina
from a 3-month-old mouse (Figure 5B) is from a 6-month-old DBA/2J mouse, (Figure 5C) is
from a 10-month-old DBA/2J mouse, and (Figure 5D) is from a 12-month-old DBA/2J mouse.
There was significant loss of RGCs in the 6, 10, and 12-month-old animals compared to the 3month-old animals. (Figure 5E) quantifies the average number of cells lost in the different age
groups. By 6 months of age, there was an average loss of 47 (SE ± 6.6) RGCs compared to 3month-old mice, representing a 16% loss. By 10 months, there was an average loss of 88 (SE ±
5.9) RGCs (a 29% loss) and by 12 months, there was an average loss of 114 (SE ± 6.0) RGCs (a
38% loss).
In this model of glaucoma, loss of RGCs was preceded by a spike in IOP within the
anterior chamber of the eye. Typical intraocular pressure measured from adult mice range from
10-20 mmHg (Savinova et al., 2001). We observed an average intraocular pressure of 10.69 (SE
± 4.0) mmHg at 3 months of age, 11.16 (SE ± 3.0) mmHg at 6 months, and 19.79 (SE ± 6.4)
mmHg at 10 months. The increase in IOP observed in the 10-month-old animals represented a
significant change compared to the IOPs from the 3 and 6-month-old animals.
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Figure 5. Progression of Retinal Ganglion Cell (RGC) Loss in DBA/2J Mice Over Time. 3, 6, 10 and
12-month-old DBA/2J mice were analyzed to quantify the increase in IOP and retinal deterioration
characteristic of the DBA/2J strain. (A) 3-month-old DBA/2J mouse retina stained with antibodies against
Thy-1.2, a marker for RGCs. Arrows indicate RGCs and double-sided arrows indicate axon bundles. (BD) 6, 10, and 12-month-old DBA/2J mouse retinas respectively show significant degeneration of the RGC
layer. (E) Quantification of RGCs at each time point. (F) IOP measurements in untreated 3, 6 and 10month-old DBA/2J mice. * represents a significant difference from 3-month-old DBA/2J controls
(p<0.01). N=5 for each condition; scale bar = 50 μm

DBA/2J retinal ganglion cells loss vs. age-related retinal ganglion cell loss
To rule out the possibility that the loss of RGCs was merely the result of natural agerelated degeneration, the average number of RGCs in 10-month-old DBA/2J retinas was
compared to 10-month old non-DBA retinas. The results shown in (Figure 2) indicate a
significantly higher loss of cells in the 10-month DBA group compared to the 10-month non-
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DBA group. (Figure 6A) shows a wild type SVJ-129 retina stained with antibodies against Thy1.2. (Figure 6B) shows an example of a 10-month-old untreated DBA retina stained with
antibodies against Thy-1.2. (Figure 6C) represents a quantification of average RGC counts for
DBA and non-DBA retinal images. The 10-month non-DBA mice had an average of 218 (SE ±
5.7) RGCs in the counted retinal images which was a significant difference from the 10-month
DBA mice, which had an average of 291 (SE ± 13.1) RGCs, representing a significant difference
of 25% between the two groups.

Figure 6. DBA-Related RGC Loss vs. Age-Related RGC Loss. Comparison of RGCs in a 10-monthold DBA/2J mouse and a 10-month-old non-DBA mouse to rule out age-related degeneration as the cause
of the DBA/2J RGC loss. (A) Untreated 10-month-old non-DBA retina stained with antibodies against
Thy-1.2. (B) Untreated 10-month-old DBA retina. (C) Quantification of RGCs between the 10-month-old
DBA and 10-month-old non-DBA groups. * represents a significant difference from 10-month-old wild
type (p<0.01). N=5 for each condition; scale bar = 50 μm

Treatment of DBA/2J mice with PNU-282987
To examine the effect of PNU-282987 on loss of RGCs in DBA/2J mice, 3, 6, and 10month-old DBA/2J mice were treated with eyedrops containing 1 mM PNU-282987 and 1
mL/mg BrdU once per day for two weeks. Following treatment, the number of RGCs was
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assessed. (Figure 7A) shows a 3-month-old DBA/2J untreated control retina while (Figure 7B-D)
show PNU-treated DBA/2J retinas at 3, 6, and 10-months-old. The retinas were stained with
anti-Thy1.2, a marker for RGCs, and anti-BrdU, a marker for cell cycle reentry. The 3-month-old
PNU treated DBA/2J mice showed a significant increase in the number of RGCs compared to the
3-month-old untreated DBA/2J controls. An average increase of 78 (SE ± 5.9) RGCs was
measured in each confocal image, representing an increase of 26%. The 10-month-old DBA/2J
mice also showed a significant increase between the treated and untreated groups. There was an
average increase of 83 (SE ± 6.7) RGCs in each image, which represents an average increase of
27%. No significant difference was found between the number of RGCs counted in images
obtained from treated and untreated 6-month-old DBA/2J mice. (Figure 7E) shows a
quantification of the number of RGCs in the different age groups and between the control and
treatment groups. (Figure 7F) illustrates quantification of the number of BrdU+ cells in each
treatment groups. No significant difference was found when comparing the number of BrdU+
cells between the different age groups that received the PNU-282987 eye drops, but a significant
difference was apparent in retinas that did not receive PNU-282987 eyedrops. The 3-month
treated DBA/2J mice showed an average of 17.4% (SE ± 2.4) BrdU+ cells compared to an
absence of BrdU+ cells in the control. Similarly, the 6-month and 10-month treated DBA/2J
retinas showed an average of 17.0% (SE ± 2.8) and 15.4% (SE ± 3.1) BrdU+ cells respectively
compared to control conditions. (Figure 5G) shows intraocular pressure (IOP) in 3, 6 and 10month-old untreated DBA/2J mice compared to 3, 6 and 10-month-old PNU treated DBA/2J
mice. IOP increased from 8.96 (SE ± 0.8) mmHg at 3 months to 15.05 (SE ± 5.2) mmHg at 6
months in PNU-282987 treated animals, but values were statistically similar to those values
obtained from untreated animals. PNU-282987 eye drop application had no significant effect on
the normal change of IOP in these DBA/2J mice.
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Figure 7. Two-Week Daily Treatment of DBA/2J Mice with PNU-282987. 3, 6, and 10-month-old
DBA/2J mice were treated once daily with PNU-282987 for two weeks. (A) Untreated 3-month-old
DBA/2J control retina stained with antibodies against Thy-1.2. (B-D) 3, 6 and 10-month-old DBA/2J
retinas treated with PNU-282987 for 2 weeks and stained with antibodies against Thy-1.2 and BrdU.
BrdU+ cells are shown in green. (E) A quantification of RGCs in treated animals compared to control
untreated animals. (F) Quantification of BrdU+ RGCs in treated 3, 6 and 10-month-old DBA/2J mice
compared to a 3-month-old DBA/2J control. (G) IOP measurements in treated and untreated 3, 6 and 10month-old DBA/2J mice. * represents a significant difference (p<0.01). N=5 for each condition; scale bar
= 50 μm.
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Effects of chronic early PNU-282987 treatment on DBA/2J RGC density
To observe the effects of repeated long-term early treatment with PNU-282987 on the
onset of the glaucoma-like condition, DBA/2J mice received weekly eye drop treatments with
PNU-282987 and BrdU before the full onset of the disease. One group received eyedrop
treatments once per week when they were 3 months of age and continued to receive treatment
until they reached 10 months of age. A second group received once-per-week treatments at 6
months of age and continued receiving treatment until 10 months of age. (Figure 8A) illustrates a
retina that began treatments at 3 months of age and (Figure 8B) illustrates a retina that began
treatments at 6 months of age. (Figure 8C) represents a quantification of the number of RGCs in
the two groups compared to the control group and the 10-month-old 2-week PNU treatment
group. We observed a significant increase in the number of RGCs in both repeated early
treatment groups compared to the control. The 3 month once-per-week treatment group showed
an average of 323 (SE ± 24.6) RGCs per retina compared to an average of 217 (SE ± 12.7) RGCs
for 10-month-old control DBA/2J mice, representing an average decrease of 32.8%. The 6 month
once-per-week treatment group showed an average of 300 (SE ± 27.5) RGCs per retina
compared to an average of 217 (SE ± 12.7) RGCs for 10-month-old control DBA/2J mice,
representing an average increase of 27.6%.
However, repeated long-term treatment groups elicited the same results as 10-month-old
mice that only received a 2-week daily PNU treatment. The two long-term treatment groups
averaged 311 RGCs, while the 10-month-old animals that received the 2-week treatment
averaged 301 RGCs per retina, representing an insignificant difference of 3.1%.
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Figure 8. Chronic Early Treatment of DBA/2J Mice with PNU-282987. 3 and 6-month-old DBA/2J
mice were treated with PNU once per week on a long-term basis to determine if early chronic treatment
can mitigate the onset of the disease (A) 10-month-old DBA/2J retina treated with PNU-282987 once per
week starting at 3 months of age until the animal was 10 months of age. Stained with antibodies against
Thy-1.2 and BrdU. (B) 10-month-old DBA/2J retina treated with PNU-282987 once per week starting at
6 months of age until the animal was 10 months of age. Stained with antibodies against Thy-1.2 and
BrdU. (C) Quantification of RGCs in the chronic early treatment groups compared to 10-month-old
DBA/2J controls and 10-month-old DBA/2J mice who received only 2 weeks of PNU treatment. *
represents a significant difference from 3-month-old controls (p<0.01). N=5 for each condition; scale bar
= 50 μm.

Effects of acute early PNU-282987 treatment on DBA/2J RGC density
The next experiment was designed to observe the effects of acute early treatment with
PNU-282987 on the onset of the glaucoma-like condition and differs from the previous
experiment in the length and frequency of treatment. The previous experiment involved onceper-week treatment over the course of months, starting before the onset of the disease. This new
experiment involved two weeks of daily PNU-282987/BrdU treatment at 3 months of age, before
the disease develops. One group received daily eyedrop treatment with PNU-282987 and BrdU
for two weeks at 3 months of age, then received no further treatment. The animals were left
alone until they reached 10 months of age, when they were sacrificed and RGC survival was
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assessed. Another group received daily eyedrop treatment with PNU-282987 for two weeks at 6
months of age, then received no further treatment until they were euthanized at 10 months.
(Figure 9) shows the effects of this acute long-term treatment with PNU-282987. (Figure 9A)
shows a retina that received acute early treatment at 3 months of age and (Figure 9B) shows a
retina that received acute early treatment at 6 months of age. (Figure 9C) shows the
quantification of the number of RGCs compared between all control and treatment groups.
Neither acute early treatment groups showed a significant difference from the untreated control
retinas. The 3-month acute PNU-282987 treatment group showed an average of 224 (SE ± 20.4)
RGCs and the 6-month acute PNU-282987 treatment group showed an average of 206 (SE ±
19.0) RGCs compared to the 10-month DBA/2J control, which showed an average of 218 (SE ±
12.7) RGCs.

Figure 9. Acute Early Treatment of DBA/2J Mice with PNU-282987. 3 and 6-month-old DBA/2J
mice were treated early with PNU-282987 for two-weeks, then left without further treatment until 10
months of age, to determine if early acute treatment can mitigate the onset of the disease (A) 10-monthold DBA/2J retina treated with PNU-282987 for 2 weeks at 3 months of age. Stained with antibodies
against Thy-1.2 and BrdU. (B) 10-month-old DBA/2J retina treated with PNU-282987 for 2 weeks at 6
months of age. Stained with antibodies against Thy-1.2 and BrdU. (C) Quantification of RGCs in 10month-old DBA/2J animals across all treatment groups. * represents a significant difference from 3month-old controls (p<0.01). N=5 for each condition; scale bar = 50 μm.
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Discussion
Based on numerous DBA/2J studies, variability in the age of onset of the glaucoma-like
conditions between different colonies of DBA/2J mice has been cited (Anderson et al., 2006;
Libby et al., 2005; Scholz et al., 2008; Turner et al., 2017). The literature describes the onset of
the disease between 6 and 10 months of age (Buckingham et al., 2008; Heiduschka et al., 2010;
Libby et al., 2005; Schlamp et al., 2006). Thus, it was necessary to establish the rate of
progression of the disease in the DBA/2J colony used in this study. DBA/2J mice of various ages
were chosen and the number of RGCs were counted to determine the best timepoints to use for
experimental treatments. Intraocular pressure was also measured as an additional metric for
determining which time points would be best suited. Some animals in the colony did not show an
increase in IOP. Therefore, only those animals that displayed an increase in IOP were used in
these experiments. 10-month-old DBA/2J mice showed the most consistent increase in IOP and
loss of RGCs. Therefore, the timepoints chosen for further experiments were 3, 6 and 10 months
old. At 3 months, the disease has not started to develop phenotypically and shows no loss of
RGCs. At 6 months, the disease has started to phenotypically develop and starts to show some
loss of RGCs. And at 10 months, the disease has fully progressed, and there was a substantial
loss of RGCs. This rate of RGC loss is consistent with previous studies (Buckingham et al.,
2008; Schuettauf et al., 2004; Wang & Dong, 2016). At 12 months, the structure of the retina
was almost totally degraded, and there were changes in cell morphology. Because of the severity
of the damage and morphological changes, 12-month-old animals were excluded from the
treatment group in these experiments. The progressive loss of RGCs across 3, 6, 10 and 12month-old DBA/2J mice and changes in IOP measurements was demonstrated in (Figure 5).
To determine that the observed RGC loss in DBA/2J mice was the result of the
progressive disease, and not just natural loss as a result of age, 10-month-old DBA/2J retinas
were compared to control retinas of the same age. (Figure 6) shows the flat-mounted retina of a
10-month-old DBA/2J (Figure 6A) compared to the flat-mounted retina of a 10-month-old wildtype mouse (Figure 6B). The number of RGCs in the 10-month DBA/2J mice was significantly
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lower than in the comparable wild-type mice (Figure 6C), suggesting that age alone was not the
driving force behind RGC loss.
Other experimental results demonstrated that PNU-282987 leads to an increase in BrdU
positive RGCs in the DBA/2J genetic mouse line. Previous studies from this lab have shown the
neurogenic effects of PNU-282987 in rats and wild-type mice, (Webster et al., 2017, 2019) but
never in the DBA/2J genetic model. Other DBA/2J studies have typically focused on
neuroprotection to prevent the loss of RGCs using various compounds (Bosco et al., 2008;
Cwerman-Thibault et al., 2017; Ward et al., 2007; Zhong et al., 2007). However, none of these
previous studies examined the potential of regeneration, which has been shown to be triggered in
these adult rodents when PNU-282987 is delivered as eye drops by acting on the RPE to release
signaling molecules that causes de-differentiation of Müller glia (Webster et al., 2017, 2019).
(Figure 7) shows DBA/2J retinas treated with PNU-282987 and BrdU. To quantify the effect of
PNU-282987, the number of total RGCs were assessed as well as the number of BrdU+ RGCs.
BrdU is used as an indicator of cells that have undergone the S-phase of the cell cycle.
Therefore, BrdU+ cells, which are shown in green, indicate newly regenerated cells in retinas
that were treated with eye drops of PNU-282987 and BrdU. Previous studies have demonstrated
that new RGCs induced by PNU-282987 originate from de-differentiation of Müller glia cells
(Webster et al., 2017, 2019). The results from this study demonstrate a significant proliferation
of RGCs in all time points compared to untreated DBA/2J controls. This indicates that PNU282987 produces consistent proliferation of RGCs across all three time points as well as a
consistent percentage of BrdU+ cells.
This study also assessed whether PNU-282987 had any effect on intraocular pressure
when administered to DBA/2J mice. As shown in the studies summarized in (Figure 7), the
change in IOP associated with different aged DBA/2J mice did not change due to PNU-282987
application. Therefore, the increase in the number of RGCs due to PNU-282987 is likely the
result of regeneration rather than a prevention of loss by a decrease in IOP.

33

After establishing the efficacy of PNU-282987, experiments were performed to
determine whether early chronic treatment could prevent the onset of the disease. In one
experiment, administration of PNU-282987 began before the onset of the disease and continued
on a weekly basis until the animal reached 10 months of age. As shown in (Figure 8), chronic
treatment with PNU-282987 in both the 3-month and 6-month animals resulted in a significant
increase of BrdU-positive RGCs. This indicates that chronic weekly treatment with PNU-282987
can significantly increase the number of RGCs in DBA/2J mice to replace the RGCs that are
typically lost due to the disease. However, acute long-term treatment with PNU-282987 failed to
indicate a significant increase in the number of RGCs from untreated control. A one-time, twoweek acute treatment of PNU-282987 applied at 3 months or 6 months of age did not
significantly affect the onset of the glaucoma-like condition in DBA/2J mice and thus, this
procedure would not be a likely therapeutic approach to replace lost RGCs in future studies.
Conclusion
This study provided evidence that long-term eye drop treatment with PNU-282987 can
offset the effects of the RGC loss observed in the characteristic glaucoma-like condition of
DBA/2J mice. However, experiments with acute early treatment indicate that repeated
administration of PNU-282987 is necessary for long-term prevention of the disease. Although
neuroprotection versus regeneration was not directly addressed in this paper, previous
publications analyzing this issue support the hypothesis that BrdU positive retinal cells induced
by eye drop application of PNU-282987 were derived from de-differentiated MG (Webster et al.,
2017, 2019). Therefore, PNU-282987 may have viable therapeutic potential as a treatment for
neurodegenerative diseases such as glaucoma when delivered on a long-term basis. Functional
studies are also underway to verify recovery of function following treatment with PNU-282987.
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CHAPTER III
DISCUSSION
In this study, we provide evidence that PNU-282987 induced BrdU-positive cells in a
genetic mouse model of glaucoma. Previous studies from this lab have shown these BrdUpositive cells arise from Müller glia cells that dedifferentiate to elicit new retinal neurons in all
layers. Induced neurogenesis or regeneration of adult mammalian neurons is rare. Throughout
the life of a mammal, new connections and synapses between existing neurons are formed as the
animal learns and grows, but rarely are new neurons developed. There are a few instances of
naturally occurring neurogenesis that have been discovered in the mammalian brain, such as in
the subgranular zone (SGZ) of the dentate gyrus within the hippocampus and the subventricular
zone (SVZ) (Alvarez-Buylla & Garcia-Verdugo, 2002; van Praag et al., 2002). Other studies
have shown evidence of a small amount of neurogenesis in the cerebellum of adult rabbits, which
may occur in humans as well, although there is yet little evidence for this (Ahlfeld et al., 2017;
Carletti & Rossi, 2008).
Further, the extent to which this neurogenesis occurs in humans and whether
hippocampal neurogenesis in humans is important for brain function is still a contentious issue.
Spalding et al. (2013)(Spalding et al., 2013) reports that a large subpopulation of hippocampal
neurons, constituting one third of the neurons, is subject to exchange in humans, with an annual
turnover of 1.75%. On the other hand, Sorrells et al. (2018)(Sorrells et al., 2018) concluded that
dentate gyrus neurogenesis in humans is extremely rare or does not occur at all. Some
neurogenesis can be artificially induced in the adult mammalian hippocampus with compounds
such as selective serotonin reuptake inhibitors (SSRI) antidepressants. Chronic treatment with
the antidepressant fluoxetine has been shown to increase the number of BrdU+ positive
hippocampal neurons in adult rats after 28 days of treatment (Malberg et al., 2000; Santarelli et
al., 2003).
However, no neurogenesis is known to naturally occur within the adult mammalian
retina. Many non-mammalian vertebrates have a robust ability to regenerate injured retinal
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neurons from Müller glia but mammalian Müller glia, by contrast, have a limited regenerative
response. Research is ongoing to understand why mammals have such a stunted regenerative
ability compared to other non-mammalian species. There is some evidence that the immune
response, specifically microglia-induced inflammation, suppresses Ascl1-induced retinal
regeneration in mice (Todd et al., 2020). Other studies have shown evidence of signaling
pathways suppressing regenerative signals via epigenetic changes. Jorstad et al. (2020)(Jorstad et
al., 2020) demonstrated that STAT signaling limits regeneration by modifying Ascl1 chromatin
binding and hampers the ability of Ascl1 to reprogram Müller glia into retinal neurons. In this
thesis study, we have induced neurogenesis artificially using PNU-282987 eye drops. Recent
studies from this lab have demonstrated that signaling molecules are released from retinal
pigment epithelium (RPE) after application of PNU-282987 eye drops to induce proliferation of
new neurons from Müller glia that come in contact with RPE (Stanchfield et al., 2020; Webster
et al., 2019).
Other attempts to induce Müller glia proliferation do so by stimulating specific
regenerative pathways. For example, in non-mammalian vertebrate retinas, the transcription
factor Achaete-scute homolog 1 (Ascl1) is upregulated following injury and has been shown to
promote regeneration. In the mammalian retina, on the other hand, Ascl1 is not upregulated
following injury. Numerous studies have demonstrated that under specific conditions,
overexpression of Ascl1 can restore some neurogenic potential in mammals (Jorstad et al., 2020;
Pollak et al., 2013; Todd et al., 2020). However, in these studies, the number of Müller glia that
are reprogrammed are very small and neurogenesis only occurs in the presence of injury (Jorstad
et al., 2017). Similarly, the transcription factor neurogenin 2 (Neurog2) is capable of converting
Müller glia into retinal ganglion cells when overexpressed in mouse Müller glia cultures
(Guimarães et al., 2018). And Yao et al. (2018) (Yao et al., 2016) demonstrated that gene
transfer of β-catenin in adult mice can activate Müller glia proliferation without retinal injury via
a Lin28/let-7 pathway. Other attempts to induce neurogenesis involve transplantation of
photoreceptor cells. These transplanted rod-precursor cells are able to migrate into the adult
retina and differentiate to acquire the specialized morphological features of mature photoreceptor
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cells and have been shown to improve vision (Gonzalez-Cordero et al., 2013; Pearson et al.,
2012).
PNU-282987 has alternatively been examined as a neuroprotective agent in the murine
retina. Cooley-Themm et al. (2017)(Cooley-Themm et al., 2017) demonstrated that acetylcholine
released from starburst amacrine cells has a neuroprotective effect on the murine retina. This
supports many other studies that have shown the neuroprotective effect of nicotine on many
different types of neurons (Dajas-Bailador et al., 2000; Kaneko et al., 1997; Nakamizo et al.,
2005). In the DBA/2J model, numerous studies have tested the efficacy of various
neuroprotective agents on the development of genetic glaucoma. Treatment with erythropoietin
prevented significant retinal ganglion cell loss, and neuroglobin, a mitochondrial protein, was
also found to have a neuroprotective effect in DBA/2J mice (Cwerman-Thibault et al., 2017;
Zhong et al., 2007). While there have been a few neuroprotection studies in the DBA/2J model,
there is currently a complete lack of regeneration or neurogenesis studies in this model.
Significance
The results of the current study indicate that acute eye drop treatment of DBA/2J mice
with PNU-282987 after the onset of retinal ganglion cell death can reverse the loss of retinal
ganglion cells associated with glaucomatous degeneration. Two-week treatment with PNU282987 at 10 months of age, which is after the onset of the disease, elicited enough BrdU
positive RGCs to counteract the cell death cause by the DBA/2J pathology. The number of
retinal ganglion cells in the 10-month-old treated DBA/2J mice was statistically the same as
healthy 3-month-old mice, indicating the therapeutic potential of PNU-282987 in treating
neurodegenerative diseases like glaucoma. Similarly, repeated early treatment with PNU-282987
before the onset of the disease can prevent the onset of the pathology. While we cannot rule out a
partial neuroprotective effect, we observe new BrdU-positive cells being formed in the retina,
indicating neurogenesis is at least partially responsible for the stability of the number of retinal
ganglion cells.

37

This is particularly significant because irreversible vision loss is such a serious public
health concern and one of the most prevalent disabilities worldwide. Blindness and visual
impairment reduce quality of life and put a huge burden on the healthcare system, costing the US
government over $22 billion a year in direct cost, loss of personal income and associated costs
such as social security (Saaddine et al., 2003). Glaucoma is the second leading cause of
irreversible vision loss worldwide after cataracts and age-related macular degeneration (Rossetti
et al., 2015). Current treatments for glaucoma are aimed at decreasing IOP to prevent retinal
ganglion cell death but these treatments can only prevent further progression of the disease, not
reverse the effects of it (Bucolo et al., 2015). Under current treatment methods, once death of
retinal ganglion cells has occurred, it is an irreversible process. Regeneration of these retinal
ganglion cells could potentially reverse the effects of glaucoma. Therefore, results from this and
other related studies could ultimately lead to use of an α7 nAChR agonist as part of a therapeutic
treatment for glaucoma.
Future directions
A number of possible follow up studies are apparent from the results of this research. The
first involves the functionality of the observed BrdU+ cells. This research establishes the
neurogenesis of new ganglion cells but we have not yet established that they make the proper
connections in the brain or improve visual function. Experiments are currently ongoing in this
lab using non-DBA mice to establish recovery of function after PNU-282987 treatment in
damaged retinas. Electroretinograms (ERGs) are used to record changes in electrical responses in
PNU-treated mice compared to control mice. By placing an electrode on the surface of the eye
and pulsating a light onto the retina of the mouse, ERGs are capable of recording the electrical
activity of the photoreceptors, bipolar cells, and retinal ganglion cells.
In addition to function, we would have also need to establish that the proper anatomical
connections are being made. To do this, we are currently utilizing a line of transgenic mice that
produce the fluorescent tdTomato protein in the Müller glia of the retina. Since newly produced
retinal neurons are derived from the Müller glia, these new neurons also express the tdTomato
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protein. Thus, staining for tdTomato along the optic nerve as well as the lateral geniculate
nucleus can establish that those new retinal ganglion cells are sending axon extensions down the
optic nerve to the lateral geniculate nucleus in PNU-282987 treated animals. Alternately,
retrograde tracing can be used to establish new extensions down the optic nerve. If the optic
nerve is severed and placed in a dye with the retina still attached, the dye will move in a
retrograde manner up the optic nerve and stain the cell bodies of the retinal ganglion cells. If the
new cells are sending extensions into the optic nerve, then the BrdU+ cell bodies will be stained
with the dye. These experiments in tandem with ERG function tests can definitively establish
that PNU-282987 restores vision within the retina.
In the DBA/2J model, further testing could be done on the BrdU+ retinal ganglion cells
to establish whether they develop into a particular subset of ganglion cells. As previously stated,
there are numerous subtypes of retinal ganglion cells that vary in morphology and function. For
example, W-type retinal ganglion cells receive excitation from a broad field of rods and are
responsible for detection of direct movement within the field whereas X-type ganglion cells are
excited by a small field of cones and detect color vision (Sanes & Masland, 2015).
This study did not differentiate between the different types of ganglion cells, as this was
not relevant to the objectives of the study. But it would be useful to know whether the density of
the different retinal ganglion cell types changes following neurogenesis or if the retina has some
mechanism for maintaining the balance between the different cell types. This would involve
more specific immune staining for the different retinal subtypes in order to be able to
differentiate them. Other future directions might involve testing PNU-282987 in other
mammalian models closer to humans, such as chimpanzees. Thus far, PNU-282987 has been
demonstrated to be effective in both a mouse and rat model, but efficacy has not been established
in animals that more closely model humans, such as primates.
Implications
This research could also lead to an increased understanding of the mechanism of
regeneration in adult mammals in both the retina and elsewhere in the body. Studies are currently
39

being performed to further elucidate the mechanisms of the observed regeneration and the
signaling pathways being utilized. The current limitation of PNU-282987 is that it cannot be
delivered systemically because it has been shown to block potassium channels in the heart,
leading to heart issues in a murine model (Walker et al., 2006).
While delivering PNU-282987 directly to the eye as eyedrops circumvents these heart
related issues, gaining an understanding of the mechanism of regeneration would possibly allow
us to generalize the observed regeneration to elsewhere in the body. And since regeneration of
neurons does not typically occur in mammals following injury, using PNU-282987 as a basis for
treating sever nerve damage, such as spinal cord injuries, could have far reaching effects on
human medical treatment.
A growing body of evidence indicates that nAChRs, specifically α7 nAChRs, play a key
role in neuroprotection within the brain against several neurodegenerative diseases (ConejeroGoldberg et al., 2008; Liu et al., 2012). There is strong evidence that α7 nAChRs are
neuroprotective, reducing β-amyloid induced toxicity in Alzheimer’s disease (Kawamata &
Shimohama, 2011; Oz et al., 2013) and that the α7 nAChRs play a role in the pathophysiology of
schizophrenia (Winterer et al., 2013; Young & Geyer, 2013). In addition, α7 nAChRs are being
studied as therapeutic targets for Parkinson’s patients (Quik et al., 2015). Therefore, a more
complex understanding of how PNU-282987 interacts with the α7 receptor might provide insight
into the treatment of these diseases as well.
To conclude, this study provides a novel examination of neurogenesis in a genetic
glaucoma model. PNU-282987 is effective at reversing the degenerative effects of the glaucomalike condition characteristic of the DBA/2J mouse. Similarly, prolonged early treatment with
PNU-282987 before the onset of the disease prevents glaucomatous damage likely through a
combination of neurogenesis and neuroprotection. Further experimentation can be done to
examine the functionality of the new cells, as well as further elucidate the specific subtypes of
retinal ganglion cells that are produced. These results could potentially lead to an effective
treatment for glaucoma and other degenerative retinal diseases.
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